VACCINES

Vaccines, Thursday 1 March 2018

08:45

Organiser's Welcome Remarks

08:50

Chair's Opening Remarks

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng
09:00

Venture capital funding for the biotech industry

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important healthcare priorities, the role of the VC becomes even more crucial and necessary for early stage biotech company and its success. Find out how venture capitalists can tap on knowledge learnt from more established biotech ecosystem and apply these lessons in Asia. 
John Connolly
09:20

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
 
Panel discussion
09:40

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?
 
10:20

Speed Networking

10:30

Exhibition Visit & Networking Refreshments

Asia immunisation program

Vaccines
10:55

Chair's Opening Remarks

Tabassum Khan
Vaccines
11:00

Role of manufacturers in clearing vaccines misconception

  •     Investigating the origin of misconception regarding vaccination
  •     Existing educational and advertising efforts and future actions required to clear such misconception
  •     Religion vs science: Is there a violation in religion to get vaccinated?
  •     Updates on halal vaccines and plans forward
Ayan Dey
Vaccines
11:20

Building affordable and sustainable vaccines framework for neglected diseases in Asia

  •     Quick overview of International Vaccine Institute (IVI) and its achievement so far
  •     Building an effective tech transfer model for quality local accessibility 
  •     Updates on IVI latest projects and collaboration opportunities
Trần Hiển Nguyễn
Vaccines
11:40

Vaccination program in Vietnam and its health impact

  •     Sharing of current and upcoming vaccination program in Vietnam
  •     Measuring success of current initiatives and strategies to improve next step in nationwide vaccination
  •     Preparing for epidemic and infectious diseases: Key steps and considerations
12:00

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 
Qun Wang
Vaccines
12:00

Case study: Development of inactivated Zika Vaccine from vero cell

  •     Overcoming challenges caused by the limited knowledge on the zika virus structure, virulent factors, and replication mechanism in its vaccine development.
  •     Updates on Changsheng Life Sciences effort in developing Zika vaccines
  •     Strategies in evaluation of vaccine efficacy and future plans moving forward

Table 1: Innovative platforms for small molecules and gene therapy drug development

Table 2: Sustainable vaccines strategies in global health, high-income and private sector

Session led by: vetter-pharma-international-gmbh

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: What can we learn fromCAR-T, PDL1, Cancer Vaccines successes, and what’s next in Asia?

Table 6: Working on a start-up setting, from clinical development to commercialisation

Table 7: AI& Big data in drug discovery

Table 8: IoT and blockchain in clinical studies

Table 10: Bringing it together: Roles of Patient, Pharma, Hospital and Government in Drug Development

Table 9: Reconciling the diversified pharma regulations in Asia

12:50

Exhibition Visit & Networking Lunch

Vaccines Manufacturing: Cost & Efficiency

Vaccines
14:10

Chair's Opening Remarks

Dr GS Reddy
Vaccines
14:20

Addressing the complexity in low cost, high volume vaccines manufacturing

    style="font-size: 10.0pt;">
  •     Exploring strategies to meet regulatory requirement in low cost, high volume quality manufacturing
  •     Cost vs innovation: How do we continuously innovate within the low profit margin business
  •     Case study and analysis
Mike Zhang
Vaccines
14:40

Challenges, innovations and opportunities in Chinese state owned vaccines company: A case study on Chengda Biotech

  •     Challenges in operating state owned vaccines company in China
  •     Key strategies forward
  •     Partnering opportunities available 
Do Tuan Dat
Vaccines
15:00

A case study of Vabiotech: Challenges in vaccine development and production in Vietnam

    style="font-size: 10.0pt;">
  •     Challenges in accessing to technology for better upstream and downstream process
  •     Strategies to help regulators keep up with new technology such as cell-based vaccines for approval
  •     Challenges in getting funding to manufacture vaccines in Vietnam
John Zeng
Vaccines
15:15

Effective technology transfer for sustainable, quality production and accessibility

  • Ensuring equity between partners and equitable TT meets both parties’ expectations
  • Freedom to operate once the recipient receive the TT to ensure production sustainability
  • Building suitable regulatory capacity for quality monitoring and approval
15:20

Exhibition Visit & Networking Refreshments

Asia Vaccine Innovation

Ines Atmosukarto
Vaccines
16:00

Targeted nanoparticle based vaccine & chemo immunotherapy drug development

Ines Atmosukarto, Chief Scientific Officer and Managing Director, Lipotek Pty Ltd
Sam Megson
Vaccines
16:40

Upscaling thermostable vaccines: Where are we now? (Topic to be confirmed)

Thermostable vaccines are an alternative solution to overcome vaccine distribution limitations in developing countries. What’s the update on progress after several years of R&D and discussion? What needs to be done to successful upscale thermostable vaccines for more efficient vaccination effort in developing regions? Case studies will also be discussed during this presentation.
Session led by: pharm-research-associates-(uk)-ltd
17:00

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 12/Jan/18 08:45

Vaccines, Friday 2 March 2018

09:00

Organiser's Welcome Remarks

09:05

Chair's Opening Remarks

Disruption & Digitalisation

Tony Liu
09:10

Shifting paradigm of the advanced therapy landscape in Asia

Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. From a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Upon approval for commercial deployment, what else needs to be done to help patients afford the sky high cost of immunotherapy? Join this thought provoking presentation to hear from Tony Liu, CEO of CBMG and former senior executive of Alibaba and Microsoft to learn how this influential biopharma company take steps to prepare for the next miracle drug in making. 
Antonio Lee
09:30

Innovation beyond limit: How do we conquer incurable diseases and create new history

Advancement in research helps to push the limitation of treatment paradigm to attempt curing currently incurable diseases. Innovative therapeutic solutions however is often not sufficient without a strong team to help with commercialisation. In this presentation, Antonio will share about the overall landscape in Asia stem cell therapy, challenges in current landscape and opportunities ahead to achieve commercial excellence.  
Ivor Lim
09:50

Educated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.
10:10

Exhibition Visit & Networking Refreshments

Vaccines
10:50

Chair's Opening Remarks

NEXT GENERATION VACCINES & DELIVERY PLATFORMS

Tim Collard
Vaccines
11:00

Low cost, flexible universal adjuvant & delivery system to orally deliver PGT and third party inactivated vaccines for infectious diseases

  •     Traditional vs new generation vaccines to protect against infectious diseases
  •     Building effective vaccines against genetic shifts and the appearance of mutated strains
  •     Moving beyond animal vaccines: How PGT platforms are being developed for human usage
Levent Liu
Vaccines
11:20

A novel platform technology for vaccine development

A core platform technology for high production of recombinant lipoproteins with built-in immuno-potentiation for novel subunit vaccine development has been established and fully protected by intellectual property. The lipid moiety of recombinant lipoproteins is identical to that of bacterial lipoproteins, which are recognized as a TLR2 agonist with effects on both innate and adaptive immunity. We have successfully demonstrated the feasibility and safety of our core platform technology in meningococcal group B subunit vaccine (MGBvac), dengue subunit vaccine and therapeutic HPV vaccine in model studies. The MGBvac has been approved by Taiwan FDA for Investigational new drug (IND). 
Paul Howley
Vaccines
11:40

Overcoming the complexities of conjugate vaccine production

  •     Exploring existing challenges in managing the complexities in conjugate vaccine production 
  •     Discovering alternative expression systems for vaccine cultivation
  •     Case study: Using in-vivo recombinant technology to produce conjugate vaccines
Vaccines
12:00

Artificial cell membrane platform technology for safer, efficient vaccine delivery

12:20

Exhibition Visit & Networking Lunch

13:40

Chair's Opening Remarks

13:45

Global Immuno-Oncology Investment Trends & Opportunities

14:05

Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma

Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.
 
Vaccines
14:05

Potential safety concerns for nucleic acid based vaccines

DNA/RNA vaccines are potential gene therapy tools which can integrate very well in plasmid and other delivery tools. However, it can also be potentially tumorigenic due to its nucleic acid nature. How do you take safety into consideration to maximise the potential of nucleic acid vaccines?
14:25

AI in pharma: Using digital technology for disease prevention

14:45

Exhibition Visit & Networking Refreshments

INNOVATION & AFFORDABILITY

Benjamin Petsch
Vaccines
15:15

Preventing infectious diseases with nucleic acid based vaccines

  • Cost effective synthesis of DNA vaccines to prevent infectious diseases
  • Using naked DNA and plasmid to induce protective immune response
  • Delivery of gene encoding vaccine antigens to stimulate infectious disease prevention
  • Vaccine design in providing rapid response time to emerging pandemics
Vaccines
15:35

Latest updates on live saving vaccine initiatives to promote local accessibility and affordability

Panel discussion
Vaccines
15:55

Keeping the sustainability of high volume, low cost quality vaccines manufacturing in Asia

  • Overview of vaccines manufacturing landscape in APAC
  • Exploring challenges and potential solutions to secure funding for manufacturing technology upgrades
  • Beyond public market: What are the other opportunities which manufacturers can tap on
  • Perspectives sharing: What are we looking for when upgrading existing platforms, and how can we collaborate better with our partners for more cost effective solutions

Close of Phar-East 2018

last published: 12/Jan/18 08:45